Corsair’s treprostinil transdermal patch for pulmonary arterial hypertension (PAH) moves closer to clinical development, Biospace, November 10, 2026
Corsair Pharma, a private company in California, had a positive pre-investigational new drug meeting with the United States Food and Drug Administration (FDA) about its once-daily treprostinil patch (TRX-248 Transdermal System) for pulmonary arterial hypertension (PAH). The Food and Drug Administration supported the company’s plan to seek approval through a shorter regulatory route (the 505(b)(2) […]

